MEMPHIS, Tenn., Nov. 7, 2016 /PRNewswire-USNewswire/ -- Long-term survivors of childhood cancer live longer thanks to improvements to cancer treatments, but a new study looking at three decades of therapy suggests patients do not report better health status. The findings from the Childhood Cancer Survivor Study (CCSS), which include feedback from a survey of more than 14,000 adult survivors treated from 1970 to 1999, appear online in Annals of Internal Medicine. "Improved survival following a diagnosis of childhood cancer is one of the success stories of modern medicine," said corresponding author Kirsten Ness, co-first author on the paper, member of the St. Jude Department of Epidemiology and Cancer Control, and CCSS investigator. "As part of our ongoing work for the Childhood Cancer Survivor Study, we wanted to investigate how survivors treated with contemporary therapy view their health status compared with survivors from earlier decades. Surprisingly, the data from the survey show a lack of improvement in perceived health status by childhood cancer survivors over the past 30 years, which serves as an important reminder that cures for cancer do not come without some consequences to patients." The Childhood Cancer Survivor Study is a multi-institutional investigation of childhood cancer survivors that has provided detailed information not only on the prevalence of disease but also on contributory factors that influence the adverse health status of cancer survivors. The cohort of patients in the CCSS was recently expanded to include individuals diagnosed between 1987 and 1999. This allowed investigators to look at how improvements to treatments have affected reported patient health over three decades. The new study involved 14,566 adult patients aged 18-48 years old who were treated for pediatric cancer in 27 institutions across North America. The analysis focused on treatments for solid tumors and cancers of the blood (including acute lymphoblastic leukemia, astrocytoma, medulloblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, rhabdomyosarcoma, Ewing sarcoma and osteosarcoma). Surgery, radiation and chemotherapy treatments were selected for evaluation. As part of the survey, patients provided feedback that described their general health, functional impairment, limits to activity, mental health, pain and anxiety. Treatment scores and adverse health status were reported as findings for 1970-79, 1980-89 and 1990-99.